Article
Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
Journal of thrombosis and haemostasis : JTH - 1 May 2012
Mancuso M E, Mannucci P M, Rocino A, Garagiola I, Tagliaferri A, Santagostino E
Abstract excerpt
BACKGROUND: Inhibitor development is influenced by several factors and the type of factor VIII (FVIII) products may play a role. OBJECTIVES: In order to explore such a role, we designed a cohort study whose novelty resides in the classification of products not only according to the source of FVIII (plasmatic, pd, or recombinant, r) but also to their degree of purity (expressed as specific activity)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
